Literature DB >> 10403535

Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells.

Y J Surh1, Y J Hurh, J Y Kang, E Lee, G Kong, S J Lee.   

Abstract

Resveratrol, a triphenolic stilbene present in grapes and other plants, has striking antioxidant and anti-inflammatory activities which have been considered to be responsible for the beneficial effects of red wine consumption on coronary heart disease. Recent studies reveal that resveratrol can inhibit each step of multistage carcinogenesis. However, the molecular mechanisms underlying anti-tumorigenic or chemopreventive activities of this phytochemical remain largely unknown. In the present work, we have found that resveratrol reduces viability and DNA synthesis capability of cultured human promyelocytic leukemia (HL-60) cells. The growth inhibitory and antiproliferative properties of resveratrol appear to be attributable to its induction of apoptotic cell death as determined by morphological and ultrastructural changes, internucleosomal DNA fragmentation, and increased proportion of the subdiploid cell population. Resveratrol treatment resulted in a gradual decrease in the expression of anti-apoptotic Bcl-2. These results, together with previous findings, suggest the cancer therapeutic as well as chemopreventive potential of resveratrol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403535     DOI: 10.1016/s0304-3835(99)00039-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  41 in total

1.  Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice.

Authors:  T L Horn; M J Cwik; R L Morrissey; I Kapetanovic; J A Crowell; T D Booth; D L McCormick
Journal:  Food Chem Toxicol       Date:  2006-08-08       Impact factor: 6.023

2.  Sparsely ionizing diagnostic and natural background radiations are likely preventing cancer and other genomic-instability-associated diseases.

Authors:  Bobby R Scott; Jennifer Di Palma
Journal:  Dose Response       Date:  2006-12-21       Impact factor: 2.658

Review 3.  Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.

Authors:  Robert Vander Broek; Grace E Snow; Zhong Chen; Carter Van Waes
Journal:  Oral Oncol       Date:  2013-10-28       Impact factor: 5.337

4.  Resveratrol-induced gene expression profiles in human prostate cancer cells.

Authors:  Sunita B Jones; Samuel E DePrimo; Michael L Whitfield; James D Brooks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

Review 5.  Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer.

Authors:  S M Hadi; M F Ullah; A S Azmi; A Ahmad; U Shamim; H Zubair; H Y Khan
Journal:  Pharm Res       Date:  2010-01-30       Impact factor: 4.200

6.  Resveratrol, a red wine constituent polyphenol, protects gastric tissue against the oxidative stress in cholestatic rats.

Authors:  Vedat Kirimlioglu; Cengiz Ara; Mehmet Yilmaz; Dincer Ozgor; Burak Isik; Gokhan Sogutlu; Hale Kirimlioglu; Aysun Bay Karabulut; Sezai Yilmaz; Cuneyt Kayaalp; Saim Yologlu
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

7.  Inhibition of citrinin-induced apoptotic biochemical signaling in human hepatoma G2 cells by resveratrol.

Authors:  Chia-Chi Chen; Wen-Hsiung Chan
Journal:  Int J Mol Sci       Date:  2009-07-29       Impact factor: 6.208

8.  Sirtuin-1 (SIRT1) is required for promoting chondrogenic differentiation of mesenchymal stem cells.

Authors:  Constanze Buhrmann; Franziska Busch; Parviz Shayan; Mehdi Shakibaei
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

9.  A DFT method for the study of the antioxidant action mechanism of resveratrol derivatives.

Authors:  Ali Benayahoum; Habiba Amira-Guebailia; Omar Houache
Journal:  J Mol Model       Date:  2013-02-03       Impact factor: 1.810

10.  Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.

Authors:  Amanda I Phipps; Qian Shi; Paul J Limburg; Garth D Nelson; Daniel J Sargent; Frank A Sinicrope; Emily Chan; Sharlene Gill; Richard M Goldberg; Morton Kahlenberg; Suresh Nair; Anthony F Shields; Polly A Newcomb; Steven R Alberts
Journal:  Int J Cancer       Date:  2016-05-09       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.